The JenaValve is a transcatheter heart valve designed specifically to treat aortic regurgitation, a condition in which the aortic valve leaks and allows blood to flow backward into the heart. What sets it apart from most other transcatheter valves is its anchoring mechanism: instead of relying on calcium deposits in a diseased valve to hold the replacement in place, the JenaValve uses small locators that clip into the natural pockets (sinuses) above the valve leaflets. That distinction matters because aortic regurgitation, unlike aortic stenosis, typically involves little or no calcification, which has historically made catheter-based valve replacement far more difficult for these patients.
Why Aortic Regurgitation Needed Its Own Valve
Transcatheter aortic valve replacement, commonly known as TAVR, transformed the treatment of aortic stenosis over the past two decades. In stenosis, the valve leaflets become stiff and calcified, narrowing the opening. That calcification is actually useful during TAVR: the replacement valve presses against it and stays anchored. Aortic regurgitation presents the opposite problem. The valve leaflets fail to close properly, but the tissue around them is often soft and pliable. Without a calcified shelf to grip, standard TAVR devices are prone to slipping out of position or migrating after deployment. The increased volume of blood flowing backward also makes the deployment environment more turbulent and unpredictable.1PubMed Central. Structural TAVI for Pure Native Aortic Regurgitation: Are We There Yet? – Section: Technical Challenges During TAVI for NPAR
For years, patients with severe aortic regurgitation who were too frail or high-risk for open-heart surgery had limited options. Surgeons sometimes used TAVR devices approved only for stenosis in an “off-label” fashion, but the results were inconsistent. The JenaValve Trilogy system was developed to close that gap by providing a valve purpose-built for the non-calcified aortic root.
How the Anchoring Mechanism Works
The JenaValve Trilogy is a self-expanding valve made from porcine pericardial tissue mounted on a nitinol frame. Its defining feature is a set of three locators that extend outward from the frame during deployment. These locators seat themselves into the aortic sinuses and engage the native valve leaflets, essentially clipping the new valve onto the existing anatomy rather than wedging it against calcified tissue. This approach allows the device to anchor securely even in the absence of calcification.2PubMed Central. Transcatheter aortic valve replacement with JenaValve Trilogy system for aortic regurgitation following a David procedure: a case report – Section: Discussion
Because the locators grab the native leaflets rather than pushing outward with brute radial force, the JenaValve exerts less pressure on the surrounding structures. That has a practical benefit for patients whose anatomy puts them at risk for complications like tearing of the aortic root (annular rupture) or blockage of the coronary artery openings. Early registry data noted that the clipping mechanism could be preferable in exactly those higher-risk anatomies.3European Journal of Cardio-Thoracic Surgery. The JUPITER registry: 1-year results of transapical aortic valve implantation using a second-generation transcatheter heart valve in patients with aortic stenosis – Section: RESULTS
The system was originally delivered through a small incision near the heart’s apex, a transapical approach. The current-generation Trilogy platform is delivered through the femoral artery in the groin, which is far less invasive and avoids the need for general anesthesia in many cases. The transfemoral version has received CE mark approval in Europe for both aortic stenosis and aortic regurgitation, and is under active investigation in the United States.4PubMed. A heart valve dedicated for aortic regurgitation: Review of technology and early clinical experience with the transfemoral Trilogy system
The ALIGN-AR Trial
The most important clinical evidence for the JenaValve in aortic regurgitation comes from ALIGN-AR, a prospective multicenter study enrolling patients with severe symptomatic aortic regurgitation who were considered high risk for conventional surgery. The trial measured safety at 30 days and all-cause mortality at one year, comparing results against performance goals derived from historical surgical outcomes.
Initial results from the first cohort of roughly 180 patients showed a 30-day safety composite event rate of about 27%, which met the prespecified performance goal. One-year mortality was about 8%, well below the 25% threshold the trial was designed to beat.5PubMed. Transcatheter aortic valve implantation in patients with high-risk symptomatic native aortic regurgitation (ALIGN-AR): a prospective, multicentre, single-arm study – Section: FINDINGS The expanded dataset, which grew to roughly 700 patients, confirmed those findings: the 30-day safety composite occurred in about 24% of patients, one-year all-cause mortality held at roughly 8%, and two-year mortality was about 13%. The trial also documented substantial reductions in aortic regurgitation severity, favorable valve function, and improvements in quality of life that persisted through two years.6The Lancet. Transcatheter aortic valve implantation in patients with high-risk symptomatic native aortic regurgitation (ALIGN-AR): a prospective, multicentre, single-arm study – Section: Summary
A few procedural safety numbers stand out from the trial. The procedural death rate was 0%, 30-day mortality was about 1.4%, valve embolization occurred in roughly 1.6% of cases, and disabling stroke at 30 days was under 1%.7Journal of the American College of Cardiology. TAVR With JenaValve for Symptomatic Aortic Regurgitation in High Surgical Risk Patients – ALIGN-AR – Section: Interpretation For a population that by definition was too sick for standard surgery, those numbers represent a meaningful advance.
Dedicated Devices Versus Off-Label TAVR for Regurgitation
Before purpose-built valves like the JenaValve existed, doctors treating severe aortic regurgitation with TAVR had to repurpose valves designed for stenosis. A meta-analysis comparing dedicated devices (including the JenaValve and J-Valve) against off-label devices found substantial differences. Dedicated devices had a 30-day mortality rate of about 3% versus 9% for off-label use, device success rates of about 93% versus 82%, and one-year all-cause mortality of roughly 6% compared with 24%. Valve embolization or migration dropped from about 8% to 2%, and the need for reintervention fell from about 10% to 4%.8PubMed. Meta-Analysis of Dedicated vs Off-Label Transcatheter Devices for Native Aortic Regurgitation – Section: RESULTS
A head-to-head comparison known as the PURPOSE study provided a more granular picture, directly matching the JenaValve Trilogy against the most commonly used off-label device. The Trilogy achieved dramatically higher technical success (about 98% versus 81%) and device success (about 95% versus 73%), driven largely by far less valve embolization (roughly 1% versus 15%) and far less moderate residual leaking (about 1% versus 10%). Interestingly, one-year mortality was similar between the two groups in that comparison, suggesting that surviving the procedure without complications may matter more than which device is in place once everything goes well.9PubMed. Performance of Purpose-Built vs Off-Label Transcatheter Devices for Aortic Regurgitation: The PURPOSE Study – Section: Results
The Pacemaker Question
One complication that comes up with nearly every TAVR device is the risk of needing a permanent pacemaker afterward. The valve sits close to the heart’s electrical conduction system, and the act of deploying it can injure the pathways that regulate heartbeat. In the ALIGN-AR trial, about 24% of patients received a new pacemaker.10PubMed. Transcatheter aortic valve implantation in patients with high-risk symptomatic native aortic regurgitation (ALIGN-AR): a prospective, multicentre, single-arm study – Section: FINDINGS That rate is notable, and it is worth understanding what drives it.
A dedicated analysis of pacemaker predictors after JenaValve implantation found that pre-existing conduction problems, specifically a first-degree atrioventricular block or a right bundle branch block, were the strongest independent predictors of needing a pacemaker. Anatomical measurements like the size of the valve annulus or the outflow tract were not predictive, and procedural factors such as how deep the valve was implanted or how much it was oversized relative to the native anatomy also showed no significant difference between patients who did and did not require pacing.11EuroIntervention. Predictors of pacemaker implantation in aortic regurgitation patients treated with a dedicated transcatheter heart valve – Section: Abstract In practice, that means the risk appears to be driven more by the patient’s baseline electrical health than by how the procedure is performed, which is useful for pre-procedural counseling but also suggests the rate may be hard to bring down through technique alone.
The PURPOSE study noted that pacemaker rates were similarly elevated for both the JenaValve Trilogy and the off-label comparator (about 24% versus 22%), suggesting this is partly a feature of doing any TAVR in an aortic regurgitation population rather than a problem unique to the JenaValve.12PubMed. Performance of Purpose-Built vs Off-Label Transcatheter Devices for Aortic Regurgitation: The PURPOSE Study – Section: Results
Hemodynamic Performance and Valve Function
Beyond just staying in place, a replacement valve needs to function well: low pressure gradients across the valve (meaning blood flows through easily) and minimal leaking around the edges. Data from the CE-mark study of the earlier transapical JenaValve showed that the average pressure gradient across the valve dropped from about 41 mmHg before the procedure to about 10 mmHg afterward, and the effective opening area more than doubled. Post-procedure, roughly 47% of patients had no detectable leak at all, another 39% had only trivial leaking, and about 14% had moderate paravalvular leakage. No patient had severe leaking.13European Journal of Cardio-Thoracic Surgery. Transapical transcatheter aortic valve implantation using the JenaValveâ„¢ system: acute and 30-day results of the multicentre CE-mark study – Section: RESULTS
Those hemodynamic numbers come from the older transapical generation, and the newer transfemoral Trilogy system has generally shown improved results in the ALIGN-AR data. The Lancet publication on the expanded cohort specifically noted favorable valve hemodynamics and evidence of beneficial heart remodeling out to two years, suggesting the heart begins to recover from the chronic volume overload that aortic regurgitation causes.14The Lancet. Transcatheter aortic valve implantation in patients with high-risk symptomatic native aortic regurgitation (ALIGN-AR): a prospective, multicentre, single-arm study – Section: Summary
Quality of Life After the Procedure
For patients living with severe aortic regurgitation, everyday activities like climbing stairs or walking to the mailbox can become exhausting. Measuring how patients actually feel after valve replacement, not just how the valve looks on imaging, is increasingly recognized as essential. Data from an early feasibility study of another dedicated device for regurgitation (the J-Valve, which shares the conceptual approach of leaflet-engaging anchoring) showed that patient-reported quality-of-life scores improved substantially: average scores rose from about 64 at baseline to about 83 at one year, and nearly all patients reported being in the mildest symptom categories at the one-year mark.15Journal of the Society for Cardiovascular Angiography & Interventions. Transcatheter Aortic Valve Replacement in Patients With Symptomatic, Severe Aortic Regurgitation: 1-Year Outcomes of the J-Valve Transfemoral Early Feasibility Study – Section: Results The ALIGN-AR trial similarly documented improvements in functional status and quality of life, though the detailed scores from that larger dataset are reported primarily in the graphical presentations rather than summary text.
Coronary Access After Implantation
One concern that grows in importance as TAVR expands to younger patients is whether doctors can still reach the coronary arteries after a replacement valve has been placed. Many patients will eventually need coronary procedures like stenting, and if the TAVR device blocks the coronary artery openings, those future procedures become difficult or impossible. The JenaValve is classified as a short stent-frame prosthesis, a category that includes other low-profile devices. Studies of coronary access after TAVR have found that short-frame valves allow successful coronary catheterization in the vast majority of cases, with success rates above 99% for the left coronary artery and around 99.6% for the right.16Journal of Asian Pacific Society of Cardiology. Managing Complex Coronary Access After Transcatheter Aortic Valve Implantation – Section: Published Data on Coronary Access and Percutaneous Coronary Intervention After Transcatheter Aortic Valve Implantation
The JenaValve Trilogy’s design elements are specifically intended to ensure both commissural alignment (meaning the new valve’s dividers line up with the native anatomy) and preserved coronary access.17PubMed. Initial Multicenter Experience With a Novel Self-Expanding TAVR System in Patients With Aortic Valve Stenosis – Section: Abstract As TAVR is increasingly performed in younger, lower-risk patients who will live with their replacement valves for decades, this design consideration becomes a significant differentiator.
The Learning Curve for Operators
Any new interventional device comes with a learning curve, and the JenaValve is no exception. Early experience with the transapical version showed that valve migration requiring a second valve occurred in a small number of cases, and operators at the time attributed this primarily to the learning curve rather than a fundamental device limitation.18European Journal of Cardio-Thoracic Surgery. Single-centre experience with next-generation devices for transapical aortic valve implantation – Section: APPENDIX. CONFERENCE DISSCUSSION
A more formal analysis of the learning curve for TAVR in aortic regurgitation patients found that proficiency stabilized after roughly 50 cases. Beyond that threshold, procedure times dropped from about 85 minutes to about 60 minutes, fluoroscopy time fell from about 12 minutes to about 6.5 minutes, and contrast dye use decreased by about 25%. Device success remained high throughout, above 96% in both the early and mature phases of the learning curve, which suggests the procedure works well even during the learning period but becomes significantly faster and uses less radiation as operators gain experience.19Clinical Cardiology. Learning curve for transcatheter aortic valve replacement for native aortic regurgitation: Safety and technical performance study – Section: Results
Regulatory Status and Where Things Stand
The JenaValve Trilogy received CE mark approval in Europe in 2021 for the treatment of severe symptomatic aortic stenosis and aortic regurgitation in patients at high surgical risk.20PubMed. The JenaValve pericardial transcatheter aortic valve replacement system to treat aortic valve disease – Section: Abstract In the United States, the FDA granted an investigational device exemption for the ALIGN-AR pivotal trial, which has since completed enrollment and reported its primary endpoints.21Society for Cardiovascular Angiography & Interventions. JenaValve Receives FDA Approval for ALIGN-AR Pivotal Trial with the Trilogy Valve for Treatment of Aortic Regurgitation The trial results, published in The Lancet, met all prespecified safety and effectiveness goals, which positions the device for potential FDA approval as the first TAVR system indicated for aortic regurgitation in the United States.
Currently, no TAVR device has FDA approval specifically for treating native aortic regurgitation in the U.S. The JenaValve Trilogy is the furthest along in that regulatory process, and the field is watching closely. A review in Structural Heart noted that dedicated devices like the JenaValve and J-Valve are “rapidly evolving,” with preliminary evidence suggesting higher procedural success and improved short-term outcomes compared with off-label approaches.22PubMed Central. Transcatheter Aortic Valve Replacement for Treating Native Aortic Regurgitation: Ready for Prime Time? – Section: Abstract
What Remains Unknown
The biggest open question is long-term durability. Biological tissue valves, whether placed surgically or via catheter, degrade over time. The ALIGN-AR data extend to two years, and some case-level data on the J-Valve (a conceptual sibling of the JenaValve with a similar leaflet-engaging design) have been reported out to five years with sustained valve function.23PubMed Central. Long-Term Outcomes and Durability of a Novel Dedicated Transcatheter Heart Valve to Treat Native Aortic Regurgitation – Section: Abstract But five years from a handful of cases is not the same as five or ten years from thousands of patients. For a technology being positioned for younger, lower-risk patients with longer life expectancies, the durability question will take time to answer fully.
There is also the question of how the device performs in anatomical edge cases. Aortic regurgitation can result from a variety of underlying conditions: dilated aortic roots, bicuspid aortic valves (where the patient is born with two leaflets instead of three), prior surgical repairs, and connective tissue disorders. The ALIGN-AR trial enrolled a specific high-risk population, and case reports have demonstrated successful JenaValve implantation after prior surgical root repair.24PubMed Central. Transcatheter aortic valve replacement with JenaValve Trilogy system for aortic regurgitation following a David procedure: a case report – Section: Discussion But broader application across the full spectrum of regurgitation etiologies will require ongoing study. Whether the device eventually moves into intermediate- or low-risk populations, as happened with TAVR for stenosis over the past decade, will depend on whether the accumulating evidence supports that expansion.